InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

Current share price for RAD : $0.012 0.001 (4.55%)+

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$50 Participation in B Riley Securities Radiopharma Conference 18 Feb 2025 8:36AM $0.025 $0.012 fallen by 54%
$50 Clinical trial data shows RAD 101 detects Brain Metastases 10 Feb 2025 8:49AM $0.025 $0.012 fallen by 54%
$50 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 11:22AM $0.026 $0.012 fallen by 55.77%
$50 Change in substantial holding 23 Jan 2025 7:41PM $0.026 $0.012 fallen by 55.77%
$50 Change in substantial holding 22 Jan 2025 11:20AM $0.027 $0.012 fallen by 57.41%
$50 Notice Under Section 708A 21 Jan 2025 1:18PM $0.026 $0.012 fallen by 55.77%
$50 Application for quotation of securities - RAD 21 Jan 2025 1:15PM $0.026 $0.012 fallen by 55.77%
$50 Response to ASX Cleansing Notice Validity Letter 20 Jan 2025 2:57PM $0.027 $0.012 fallen by 57.41%
$50 Lantheus increases shareholding in RAD with A$8m placement 10 Jan 2025 9:07AM $0.024 $0.012 fallen by 52.08%
$50 Strategic Co-Development Partnership with Lantheus for Aus 30 Dec 2024 9:02AM $0.023 $0.012 fallen by 50%
$50 RAD 202 receives approval to start Phase 1 therapeutic trial 20 Dec 2024 8:51AM $0.021 $0.012 fallen by 45.24%
$50 Notice Under Section 708A 19 Dec 2024 3:40PM $0.022 $0.012 fallen by 47.73%
$50 Application for quotation of securities - RAD 19 Dec 2024 3:35PM $0.022 $0.012 fallen by 47.73%
$50 Response to ASX Aware Letter 19 Dec 2024 9:31AM $0.023 $0.012 fallen by 50%
$50 Notification of cessation of securities - RAD 18 Dec 2024 3:58PM $0.023 $0.012 fallen by 50%
$50 Change of Director's Interest Notices x7 18 Dec 2024 3:42PM $0.024 $0.012 fallen by 51.06%
$50 Notification regarding unquoted securities - RAD 18 Dec 2024 3:38PM $0.024 $0.012 fallen by 51.06%
$50 Application for quotation of securities - RAD 18 Dec 2024 2:53PM $0.024 $0.012 fallen by 51.06%
$50 Change of Director's Interest Notice PH 10 Dec 2024 4:57PM $0.033 $0.012 fallen by 65.15%
$50 Completion of preclinical data package for RAD 402 10 Dec 2024 9:59AM $0.041 $0.012 fallen by 71.95%
$50 Constitution 2 Dec 2024 5:05PM $0.028 $0.012 fallen by 58.93%
$50 Notification of cessation of securities - RAD 2 Dec 2024 5:03PM $0.028 $0.012 fallen by 58.93%
$50 Radiopharm achieves Nasdaq listing of ADS 27 Nov 2024 8:23AM $0.028 $0.012 fallen by 58.93%
$50 Results of Meeting 25 Nov 2024 12:07PM $0.027 $0.012 fallen by 57.41%
$50 Presentation to Annual General Meeting 25 Nov 2024 8:27AM $0.025 $0.012 fallen by 54%

126 - 150 of 612 results

Page 6 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.